Navigation Links
Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
Date:4/15/2008

differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "preliminary"; "interim"; "potential"; "may"; or similar statements are forward-looking statements. Medarex disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risks associated with product development, unforeseen safety issues resulting from the administration of antibody products in humans, as well as risks detailed from time to time in Medarex's public disclosure filings with the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the fiscal year ended December 31, 2007 and its quarterly reports on Form 10-Q. There can be no assurance that future milestone payments will be paid, whether the product development efforts will succeed, or whether other developed products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success. Copies of Medarex's public disclosure filings are available from its investor relations department.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.


'/>"/>
SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
2. Medarex to Receive Milestone Payment from Amgen
3. Medarex Announces Ipilimumab Program Continues to Move Forward
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Spherix Reports Second Quarter Earnings
6. Tapestry Reports Second Quarter 2007 Results
7. Callisto Reports on Second-Quarter 2007 Milestones
8. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
9. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
10. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
11. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/15/2008)...TON, May 15 /- CenterWatch, a publish...rket research about clinical,trials, finds that in...DC,(electronic data capture) systems. More than 75...dicated that they had been trained on three or mor...hat the effectiveness of,their EDC training had im...
(Date:5/15/2008)...KVILLE, Md., May 15 /- Nova...as completed enrollment in the Phase I/IIa,study o... of approximately,230 subjects. Favorable interim ...ncluded dose-escalation in 70 healthy adult volunt...findings suggested that the vaccine,is well tolera...
(Date:5/15/2008)...e Advantage Fee-For-Service Plan Positions Blue Cr...ss, According to a New Report from ...., May 15 /- HealthLeaders-InterStudy...lligence, reports that as the,economy continues to...ichigan remains the best equipped of all of its co...
(Date:5/15/2008)...domized TRIAS HR Pilot Study Compares Genous, Bost...us(R), Other Presentations Focus on Real-World Use...AMI, Those Who Could Not Tolerate Dual-Antiplatele...NA, Spain, May 15 /- OrbusNeich today...ns in a symposium at EuroPCR 2008,support the use ...
Breaking Medicine Technology:CenterWatch Releases State of the Clinical Trials Industry 2008 - A Key Industry Resource for Market Research and Competitive Intelligence 2Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial 2Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial 3Blue Cross Blue Shield Of Michigan Battles Sluggish Economy With Diverse Product Lineup 2Multiple Clinical Data Presentations at EuroPCR 2008 Support Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) as Safe Alternative to Drug-Eluting Stents 2Multiple Clinical Data Presentations at EuroPCR 2008 Support Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) as Safe Alternative to Drug-Eluting Stents 3Multiple Clinical Data Presentations at EuroPCR 2008 Support Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) as Safe Alternative to Drug-Eluting Stents 4U S Advisers OK Nasal Spray Flu Vaccine for Young Children 4523 1U S Advisers OK Nasal Spray Flu Vaccine for Young Children 4523 2U S Advisers OK Nasal Spray Flu Vaccine for Young Children 4523 3WellPoint Taps Zagat Survey to Help Consumers Rate Experiences with Their Doctors 4520 1WellPoint Taps Zagat Survey to Help Consumers Rate Experiences with Their Doctors 4520 2WellPoint Taps Zagat Survey to Help Consumers Rate Experiences with Their Doctors 4520 3Blue Cross of California Foundation Donates 2450 000 to American Red Cross 4517 1Blue Cross of California Foundation Donates 2450 000 to American Red Cross 4517 2New Oral MEK Inhibitor RDEA119 Shows Favorable Anti Tumor Properties 1474 1New Oral MEK Inhibitor RDEA119 Shows Favorable Anti Tumor Properties 1474 2New Oral MEK Inhibitor RDEA119 Shows Favorable Anti Tumor Properties 1474 3New Oral MEK Inhibitor RDEA119 Shows Favorable Anti Tumor Properties 1474 4
(Date:5/16/2008)...m an international, multicenter Phase III clinical...erapy everolimus (RAD001) significantly delays can... cancer whose disease had worsened on other treatm...attending physician at Memorial Sloan-Kettering Ca... on May 31 at the annual meeting of the American S...
(Date:5/16/2008)...ds located just beneath the lining of the uterus (...rial cavity after uterine artery embolization (UAE...rding to a new study. , The study included 49 p...mination before and after UAE. The study found tha...ted to the endometrial cavity after UAE, said Sach...
(Date:5/16/2008)... Fundraiser Seeks to Raise $38 Million for Life-th...ire-USNewswire/ -- Walkers in nearly,every state w...- May 17 and,18 -- by participating in GREAT STRID...c Fibrosis Foundation announced today., May is Na...rosis is a,life-threatening genetic disease that c...
(Date:5/16/2008)... Haag,s Statement for National HIV Vaccine Awarene...Newswire/ -- Twenty-six years into the,AIDS epidem...nutes in the,U.S. On Sunday, May 18, HIV Vaccine A...rtners in the National Institute of Allergy and In...ation Initiative, urges everyone,to help end the A...
Breaking Medicine News(10 mins):Health News:Drug fends off kidney cancer progression 2Health News:GREAT STRIDES Walks for Cystic Fibrosis Slated for 47 States This Weekend 2Health News:AIDS Action Urges Everyone to Help End the AIDS Epidemic by Being Part of the Search for an HIV Vaccine 2
...ith Leukemia has urged MSPs to intervene to stop n... power lines//. The charity said that health conce...s in such areas. "It's a very clear message for t...hose Scottish people not affected want a moratoriu...
...enhanced their cooperation in the crucial area of ...ight polio and avian flu. // "The two sides disc...ideas on management of avian influenza," external ...on Navtej Sarna said. During the first meeting o...
...uy Swedish medical company Biacore to complement i...companies have announced. // The Fairfield, Conne...alises in instruments for medical research, for 3.... ($438 million). Pharmaceutical company Pfizer I...
...alarial deaths in Jharkhand's Sahibganj district, ...-led NDA // , today urged the health department to...artment should at the earliest direct its medical ... Sahibganj due to malaria and the disease has affl...
Other Medicine News:
...3 mm is a resorbable repair device used in conjunc...ng device to attach soft tissue to bone using sutu... a prepared hole in the bone, and is used to attac... a resorbable copolymer, derived from glycolide an...
This type of anchor is generally used when anchor size may be an issue. This 2.9mm anchor is packaged sterile and comes pre-loaded with sutures (1-0 or 2-0) and needles. Although pre-drilling is not
...ile Anchor is a nonabsorbable repair device to att...is implanted into a prepared hole in the bone and ...rs are manufactured from Titanium (6AL4V ELI) allo...e coated with Titanium Nitride (TiN) which conform...
The MINI-TAG™ instrument systems are indicated for ulnar collateral ligament repair, scapholunate dissolution, flexor avulsions, and carpometa-carpal arthroplasty.
Medicine Products: